Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by substantial clinical and immunological heterogeneity. Traditionally considered a disorder of epidermal barrier dysfunction primarily, AD is now increasingly recognized as a complex systemic inflammatory condition involving dysregulated immune responses, epithelial-derived signaling, neuroimmune interactions, and diverse molecular endotypes. Advances in molecular immunology have significantly expanded current understanding of the cytokine networks underlying disease pathogenesis and have accelerated the transition toward precision medicine approaches in AD. This narrative review summarizes current evidence regarding the immunopathogenesis of AD, with particular emphasis on the interplay between classical and emerging cytokines, biomarker development, and recent therapeutic innovations. Classical type 2 cytokines, including interleukin (IL)-4 and IL-13, remain central drivers of allergic inflammation and epidermal barrier impairment, whereas emerging mediators such as IL-31, IL-33, IL-22, thymic stromal lymphopoietin (TSLP), and OX40/OX40L signaling pathways contribute significantly to chronic inflammation, neuroimmune activation, epidermal remodeling, and pruritus. Comparative analysis of these cytokine pathways highlights the molecular heterogeneity of AD and supports the identification of distinct immunological endotypes. The review additionally discusses current and emerging biomarkers associated with disease severity, therapeutic responsiveness, and inflammatory profiling, including cytokine signatures, serum biomarkers, and transcriptomic approaches. Furthermore, major therapeutic advances involving biologic agents and Janus kinase (JAK) inhibitors are examined within the context of mechanism-based and biomarker-guided therapeutic strategies. Importantly, this review proposes a conceptual precision medicine framework integrating immunopathogenesis, cytokine profiling, molecular endotyping, and targeted therapeutic innovation in AD. Continued advances in biomarker discovery, multi-omics technologies, and individualized therapeutic algorithms may further refine disease stratification and improve personalized management strategies for patients with AD.